Verisante Technology, Inc. Partners with the BC Cancer Foundation to Showcase Aura(TM) for Skin Cancer Detection
June 10 2014 - 9:30AM
Marketwired
Verisante Technology, Inc. Partners with the BC Cancer Foundation
to Showcase Aura(TM) for Skin Cancer Detection
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 10, 2014) -
Verisante Technology, Inc. (TSX-VENTURE:VRS)(OTCQX:VRSEF) (the
"Company" or "Verisante"), a leader in cancer detection technology,
announced today that the Company is partnering with the BC Cancer
Foundation to showcase Verisante Aura™, a device for the detection
of skin cancer.
"We are very appreciative of the BC Cancer Foundation's support
for Verisante and for Aura™ and also for the Foundation's
dedication to raising funds that support innovative research
directed at achieving the highest standard of care for every
patient facing cancer in B.C.," said Thomas Braun, President &
CEO of Verisante Technology, Inc.
Verisante has placed an Aura™ at the Foundation's Provincial
Office in Vancouver for display and educational purposes.
"Our unique relationship with the BC Cancer Agency allows our
donors to be part of research discoveries made right here in
British Columbia," said Douglas Nelson, President & CEO of the
BC Cancer Foundation. "Verisante Aura™ is one of those 'made in
BC' inventions coming out of the leading edge technology and
research efforts of the BC Cancer Agency. Our Foundation is pleased
to have the opportunity to demonstrate and promote this exciting
technology."
The BC Cancer Foundation funds the areas of greatest priority
and promise, as identified by the scientists and clinicians at the
BC Cancer Agency, who look for priorities and needs that will have
the most significant and timely impact on cancer care and
treatment. The Foundation then partners with donors to raise the
necessary funds in support of this life-saving work. Together with
its partners, the Foundation is funding and finding solutions that
are having a direct impact on improving care for cancer patients in
British Columbia.
About the BC Cancer
Foundation
The BC Cancer Foundation is the bridge that connects
philanthropic support and research breakthroughs in cancer
knowledge. As the fundraising partner of the BC Cancer Agency and
the largest charitable funder of cancer research in this province,
we enable donors to make contributions to leading-edge research
that has a direct impact on improvements to cancer care for
patients in British Columbia. We fund with the goal of finding
solutions.
As an independent charitable organization, we raise funds
exclusively for the BC Cancer Agency that support innovative cancer
research and compassionate enhancements to patient care.
Visit www.bccancerfoundation.com to make a donation or to learn
how you can make a difference in the lives of those affected by
cancer.
About Verisante
Technology, Inc.
Verisante is a medical device company committed to
commercializing innovative systems for the early detection of
cancer. The Verisante Aura™ for skin cancer detection and the
Verisante Core™ series for lung, colon and cervical cancer
detection utilize a proprietary cancer detection platform, while
the operating software and probe technology are unique to each
device. The cancer detection platform was developed by the BC
Cancer Agency and tested and refined at the Skin Care Centre at
Vancouver General Hospital. This exclusive platform technology
allows Verisante to develop and offer a range of compact,
non-invasive cancer detection devices that offer physicians
immediate results for many of the most common cancers. Aura™ has
been approved for sale in Canada, Europe and Australia. Core™ has
not yet been approved for sale.
Verisante Aura™ was awarded the 2014 North American Technology
Innovation of the Year Award for In Vivo Cancer Detection by
Frost & Sullivan, Popular Science Magazine's
"Best of What's New Award" for 2011, awarded a 2013 Prism Award for
Innovation in Photonics and an Edison Award for Excellence in
Innovation in 2013. Verisante Core™ was named one of the top 10
cancer breakthroughs of 2011 by the Canadian Cancer Society.
The TSX Venture Exchange has neither approved nor
disapproved of the contents of this press release. Neither the TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this press
release.
Forward Looking Statements
This release contains forward-looking statements, including, but
not limited to, statements regarding the future commercialization
of medical devices, the market demand for these products and the
proprietary protections the Company will obtain with regard to the
technology, all of which statements are subject to market risks,
and the possibility that the Company will not be able to obtain
patent protection or obtain sufficient customer demand. These
statements are made based upon current expectations and actual
results may differ from those projected due to a number of risks
and uncertainties.
Thomas Braun, President & CEOVerisante Technology,
Inc.Telephone: (604) 605-0507Email: info@verisante.comWebsite:
www.verisante.comYouTube: www.youtube.com/verisanteTwitter:
www.twitter.com/verisanteFacebook: www.facebook.com/verisante
Verisante Technology (TSXV:VRS)
Historical Stock Chart
From May 2024 to May 2024
Verisante Technology (TSXV:VRS)
Historical Stock Chart
From May 2023 to May 2024
